SOLT.F Stock Overview
Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.05 |
| 52 Week High | JP¥13.43 |
| 52 Week Low | JP¥7.00 |
| Beta | 0.63 |
| 11 Month Change | 5.39% |
| 3 Month Change | n/a |
| 1 Year Change | -19.48% |
| 33 Year Change | -61.68% |
| 5 Year Change | n/a |
| Change since IPO | -81.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOLT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | -19.5% | 9.9% | 31.6% |
Return vs Industry: SOLT.F underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: SOLT.F underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| SOLT.F volatility | |
|---|---|
| SOLT.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SOLT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SOLT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 372 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
| SOLT.F fundamental statistics | |
|---|---|
| Market cap | US$657.25m |
| Earnings (TTM) | -US$23.97m |
| Revenue (TTM) | US$189.07m |
3.5x
P/S Ratio-27.4x
P/E RatioIs SOLT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOLT.F income statement (TTM) | |
|---|---|
| Revenue | JP¥29.28b |
| Cost of Revenue | JP¥5.43b |
| Gross Profit | JP¥23.85b |
| Other Expenses | JP¥27.56b |
| Earnings | -JP¥3.71b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -41.28 |
| Gross Margin | 81.46% |
| Net Profit Margin | -12.68% |
| Debt/Equity Ratio | 95.8% |
How did SOLT.F perform over the long term?
See historical performance and comparison